Publications by authors named "Samar Mowafy"

Claim this Profile
L
Ligand-based discovery of novel N-arylpyrrole derivatives as broad-spectrum antimicrobial agents with antibiofilm and anti-virulence activity.
Basma M Qandeel, Samar Mowafy, Mohamed F El-Badawy, Nahla A Farag, Galal Yahya

J Enzyme Inhib Med Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical signatures of disease severity in multiple sulfatase deficiency.
Laura A Adang, Samar Mowafy, Zackary M Herbst, Zitao Zhou, Lars Schlotawa

J Inherit Metab Dis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Camptothecin structure simplification elaborated new imidazo[2,1-b]quinazoline derivative as a human topoisomerase I inhibitor with efficacy against bone cancer cells and colon adenocarcinoma.
Ahmed I Khodair, Salwa M El-Hallouty, Brittnee Cagle-White, May H Abdel Aziz, Mahmoud Kh Hanafy, Samar Mowafy

Eur J Med Chem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead generation of UPPS inhibitors targeting MRSA: Using 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamic simulations.
Basma M Qandeel, Samar Mowafy, Khaled Abouzid, Nahla A Farag

BMC Chem· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector.
Courtney J Rouse, Kimberley Hawkins, Nadia Kabbej, Justin Dalugdug, Aishwarya Kunta, Samar Mowafy

Hum Mol Genet· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation.
Asmaa Raafat, Samar Mowafy, Sahar M Abouseri, Marwa A Fouad, Nahla A Farag

Comput Biol Med· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular design, synthesis and biological evaluation of thienopyrimidine-hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer.
Mona M Abdel-Atty, Nahla A Farag, Rabah A T Serya, Khaled A M Abouzid, Samar Mowafy

J Enzyme Inhib Med Chem· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural Basis of Selective Human Indoleamine-2,3-dioxygenase 1 (hIDO1) Inhibition.
Shaymaa Emam Kassab, Samar Mowafy

ChemMedChem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Shaymaa E Kassab, Samar Mowafy, Aya M Alserw, Joustin A Seliem, Shahenda M El-Naggar

J Enzyme Inhib Med Chem· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
Mahitab K Sobhy, Samar Mowafy, Deena S Lasheen, Nahla A Farag, Khaled A M Abouzid

Bioorg Chem· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-guided development of covalent TAK1 inhibitors.
Li Tan, Deepak Gurbani, Ellen L Weisberg, John C Hunter, Lianbo Li, Samar Mowafy

Bioorg Med Chem· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.
Li Tan, Deepak Gurbani, Ellen L Weisberg, Douglas S Jones, Suman Rao, Samar Mowafy

Bioorg Med Chem· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
Samar Mowafy, A Galanis, Zainab M Doctor, Raymond M Paranal, Deena S Lasheen

Bioorg Med Chem· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
Samar Mowafy, Nahla A Farag, Khaled A M Abouzid

Eur J Med Chem· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis